Cargando…
Case report: Successful use of mepolizumab for immune checkpoint inhibitors–induced hypereosinophilic syndrome in two patients with solid malignancies
Hypereosinophilic syndrome (HES) represents a group of blood disorders characterized by an absolute eosinophil count (AEC) > 1.5 × 103/μl in the peripheral blood, which eventually extravasate and cause organ damage. It can be primary or secondary to infections or tumors. The infiltration of eosin...
Autores principales: | Lazzari, Chiara, Yacoub, Mona Rita, Campochiaro, Corrado, Bulotta, Alessandra, Palumbo, Diego, Ogliari, Francesca Rita, Dagna, Lorenzo, Marchesi, Silvia, Ponzoni, Maurilio, Gregorc, Vanesa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9911301/ https://www.ncbi.nlm.nih.gov/pubmed/36776300 http://dx.doi.org/10.3389/fonc.2023.1079034 |
Ejemplares similares
-
Dysphonia and dyspnea in idiopathic hypereosinophilic syndrome treated with Mepolizumab
por: Kay, Dana, et al.
Publicado: (2018) -
Mepolizumab in Hypereosinophilic Syndrome: A Systematic Review and Meta-analysis
por: Alves, José Mario, et al.
Publicado: (2021) -
Characterization of disease flares and impact of mepolizumab in patients with hypereosinophilic syndrome
por: Pane, Fabrizio, et al.
Publicado: (2022) -
Idiopathic hypereosinophilic syndrome in remission with benralizumab treatment after relapse with mepolizumab
por: Fujii, Koki, et al.
Publicado: (2020) -
Mepolizumab therapy improves the most bothersome symptoms in patients with hypereosinophilic syndrome
por: Roufosse, Florence, et al.
Publicado: (2023)